Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Promising pancreatic cancer trial results announced by Verastem

Published 24/05/2024, 07:20 am
© Reuters.
VSTM
-

BOSTON - Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company, has announced promising interim results from its ongoing RAMP 205 Phase 1/2 clinical trial, which is testing a new drug combination for the treatment of metastatic pancreatic cancer. As of May 14, 2024, 83% of patients in the first cohort achieved a confirmed partial response to the combination therapy, which includes avutometinib and defactinib with gemcitabine and Nab-paclitaxel.

The initial findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. The study is significant as it explores the effectiveness of targeting the RAS/MAPK pathway, which is relevant in more than 90% of pancreatic tumors known to have a KRAS mutation.

Despite one dose-limiting toxicity observed, the dose level was cleared for further investigation after more patients were enrolled. The trial continues to evaluate additional dose and schedule regimens to establish the recommended Phase 2 dose.

Metastatic pancreatic cancer, a stage IV cancer that has spread to other organs, is notoriously difficult to treat, with a 5-year survival rate of only 3% in the U.S. Verastem's trial is supported by the PanCAN Therapeutic Accelerator Award, highlighting the urgency to develop more effective treatments.

The trial has enrolled patients across four dose and schedule cohorts, with the most mature cohort showing a confirmed partial response rate of 83%. Treatment emergent serious adverse events were reported, including one case of febrile neutropenia as a dose-limiting toxicity. However, most patients in the recently enrolled cohorts remained on treatment as of the data cutoff.

Verastem Oncology will hold an investor conference call and webcast on Friday, May 24, 2024, at 8:00 am EDT to discuss these interim results. The company's focus is on advancing new medicines that inhibit signaling pathways in cancer, with a particular emphasis on RAS/MAPK-driven cancers.

InvestingPro Insights

As Verastem Oncology (NASDAQ:VSTM) presents its interim results for the RAMP 205 Phase 1/2 clinical trial at the upcoming ASCO Annual Meeting, investors and industry observers are closely monitoring the company's financial health and market performance. According to recent data from InvestingPro, Verastem Oncology holds a market capitalization of approximately $308.25 million, with a negative price-to-earnings (P/E) ratio of -2.72, reflecting the company's current lack of profitability.

The company's stock has experienced a strong return over the last year, with a 116.06% price total return, and a significant 45.95% year-to-date price total return as of 2024. However, it's important to note that Verastem is trading at a high Price / Book multiple of 12.3, which could indicate that the stock is valued quite richly in relation to the company's book value.

Two InvestingPro Tips that could be particularly relevant for investors considering Verastem Oncology are:

  • The company holds more cash than debt on its balance sheet, which could provide some financial flexibility in its operations and research development.
  • However, analysts have concerns about the company's profitability, with expectations that net income may drop this year and no anticipation of profitability within the year.

For investors seeking a deeper dive into Verastem Oncology's financials and market outlook, there are additional InvestingPro Tips available. By visiting InvestingPro's dedicated page for VSTM, you can access a comprehensive list of insights. For those interested in an InvestingPro subscription, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.